Czech Republic | BCH-RA-CZ-115675 | Risk Assessment generated by a regulatory process | Biosafety Clearing-House

Loading...
  |  
BCH-RA-CZ-115675-1   |   PDF   |   Print   |  

Risk Assessment generated by a regulatory process (RA)

last updated: 11 Aug 2020
General Information
Risk assessment of GM barley producing LL-37 peptide
EN
28 Jan 2019
Risk assessment details
  • Barley modified for the production of LL-37 peptide
    | Palacky University Olomouc | Production of medical or pharmaceutical compounds (human or animal), Resistance to antibiotics (Hygromycin), Selectable marker genes and reporter genes
  • Barley modified for the production of LL-37 peptide
    | Palacky University Olomouc | Production of medical or pharmaceutical compounds (human or animal), Resistance to antibiotics (Hygromycin), Selectable marker genes and reporter genes
  • Barley modified for the production of LL-37 peptide
    | Palacky University Olomouc | Production of medical or pharmaceutical compounds (human or animal), Resistance to antibiotics (Hygromycin), Selectable marker genes and reporter genes
Methodology and points to consider
EN
EN
EN
The transgenic plants producing the LL-37 peptide (T1-T3 generation) were grown in a closed phytotron and in greenhouses of the Palacký University (Department of Molecular Biology) in Olomouc within contained GMO use management. No selective advantages or disadvantages, nor any interactions with
control plants or other organisms were observed for the selected modifications (UBI:LL-37, bHOR:LL-37 and bHOR:MBPLL-37).
The modified spring barley does not pose any risks to the environment, nor to any risks to human health or animal health.
EN
EN
EN
Czech Republic, region Olomouc, Cadastral teritory Mohelnice
EN
EN
Additional information
EN
Loading...